Fulcrum Therapeutics (NASDAQ:FULC) Director Sells $65,700.00 in Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the transaction, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. This represents a 62.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Fulcrum Therapeutics Stock Up 5.5%

Shares of NASDAQ:FULC opened at $3.84 on Friday. The company has a market cap of $255.86 million, a P/E ratio of -3.34 and a beta of 3.01. Fulcrum Therapeutics, Inc. has a 52 week low of $2.83 and a 52 week high of $15.74. The business has a fifty day simple moving average of $5.41 and a 200-day simple moving average of $8.05.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

A number of institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new stake in Fulcrum Therapeutics during the 1st quarter worth approximately $292,000. Westshore Wealth LLC acquired a new position in Fulcrum Therapeutics during the first quarter valued at approximately $130,000. The Manufacturers Life Insurance Company grew its stake in Fulcrum Therapeutics by 25.0% during the first quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock worth $124,000 after buying an additional 3,219 shares during the period. Pale Fire Capital SE purchased a new stake in Fulcrum Therapeutics during the first quarter worth approximately $200,000. Finally, Siren L.L.C. increased its position in shares of Fulcrum Therapeutics by 20.5% in the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 400,000 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on FULC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. Citigroup lowered shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target on the stock. in a report on Tuesday, June 2nd. Finally, Truist Financial cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $8.20.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.